Image 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …"

Table 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …"

Table 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …"

Table 4_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …"

Image 1_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …"

Image 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …"

Table 1_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …"

Image 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …"

Regional work heterogeneity in LBBB differs between responders and non-responders, but LV stroke work, myocardial work, and efficiency do not. حسب Amanda Craine (19832365)

"…(D) Regional work heterogeneity (COVW) was significantly (p<0.05) higher at baseline in responders than non-responders and only decreased significantly after CRT (p = 0.05) in the responder group.…"

Proteomic and Lipidomic Plasma Evaluations Reveal Biomarkers for Domoic Acid Toxicosis in California Sea Lions حسب Amie M. Solosky (20320255)

"…Domoic acid is a neurotoxin secreted by the marine diatom genus <i>Pseudo-nitzschia</i> during toxic algal bloom events. …"

Proteomic and Lipidomic Plasma Evaluations Reveal Biomarkers for Domoic Acid Toxicosis in California Sea Lions حسب Amie M. Solosky (20320255)

"…Domoic acid is a neurotoxin secreted by the marine diatom genus <i>Pseudo-nitzschia</i> during toxic algal bloom events. …"

Tandem Imaging of Breath Ethanol and Acetaldehyde Based on Multiwavelength Enzymatic Biofluorometry حسب Kenta Iitani (4175995)

"…Reduction of AcH by ADH_RD consumed NADH, leading to a decrease in blue fluorescence (ex. 340 nm, fl. 490 nm). …"

Tandem Imaging of Breath Ethanol and Acetaldehyde Based on Multiwavelength Enzymatic Biofluorometry حسب Kenta Iitani (4175995)

"…Reduction of AcH by ADH_RD consumed NADH, leading to a decrease in blue fluorescence (ex. 340 nm, fl. 490 nm). …"

Tandem Imaging of Breath Ethanol and Acetaldehyde Based on Multiwavelength Enzymatic Biofluorometry حسب Kenta Iitani (4175995)

"…Reduction of AcH by ADH_RD consumed NADH, leading to a decrease in blue fluorescence (ex. 340 nm, fl. 490 nm). …"

Tandem Imaging of Breath Ethanol and Acetaldehyde Based on Multiwavelength Enzymatic Biofluorometry حسب Kenta Iitani (4175995)

"…Reduction of AcH by ADH_RD consumed NADH, leading to a decrease in blue fluorescence (ex. 340 nm, fl. 490 nm). …"

Tandem Imaging of Breath Ethanol and Acetaldehyde Based on Multiwavelength Enzymatic Biofluorometry حسب Kenta Iitani (4175995)

"…Reduction of AcH by ADH_RD consumed NADH, leading to a decrease in blue fluorescence (ex. 340 nm, fl. 490 nm). …"

Tandem Imaging of Breath Ethanol and Acetaldehyde Based on Multiwavelength Enzymatic Biofluorometry حسب Kenta Iitani (4175995)

"…Reduction of AcH by ADH_RD consumed NADH, leading to a decrease in blue fluorescence (ex. 340 nm, fl. 490 nm). …"

Tandem Imaging of Breath Ethanol and Acetaldehyde Based on Multiwavelength Enzymatic Biofluorometry حسب Kenta Iitani (4175995)

"…Reduction of AcH by ADH_RD consumed NADH, leading to a decrease in blue fluorescence (ex. 340 nm, fl. 490 nm). …"

Tandem Imaging of Breath Ethanol and Acetaldehyde Based on Multiwavelength Enzymatic Biofluorometry حسب Kenta Iitani (4175995)

"…Reduction of AcH by ADH_RD consumed NADH, leading to a decrease in blue fluorescence (ex. 340 nm, fl. 490 nm). …"

Tandem Imaging of Breath Ethanol and Acetaldehyde Based on Multiwavelength Enzymatic Biofluorometry حسب Kenta Iitani (4175995)

"…Reduction of AcH by ADH_RD consumed NADH, leading to a decrease in blue fluorescence (ex. 340 nm, fl. 490 nm). …"